Clifford Swan Investment Counsel LLC trimmed its position in Novartis (NYSE:NVS) by 0.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 130,312 shares of the company’s stock after selling 850 shares during the quarter. Clifford Swan Investment Counsel LLC’s holdings in Novartis were worth $10,536,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Garland Capital Management Inc. boosted its holdings in Novartis by 1.0% in the 4th quarter. Garland Capital Management Inc. now owns 52,233 shares of the company’s stock valued at $4,385,000 after purchasing an additional 535 shares during the last quarter. Tradition Capital Management LLC boosted its holdings in Novartis by 0.9% in the 4th quarter. Tradition Capital Management LLC now owns 69,381 shares of the company’s stock valued at $5,825,000 after purchasing an additional 652 shares during the last quarter. Commerce Bank boosted its holdings in Novartis by 2.4% in the 4th quarter. Commerce Bank now owns 28,004 shares of the company’s stock valued at $2,352,000 after purchasing an additional 664 shares during the last quarter. Abbot Financial Management Inc. boosted its holdings in Novartis by 2.5% in the 1st quarter. Abbot Financial Management Inc. now owns 28,769 shares of the company’s stock valued at $2,326,000 after purchasing an additional 700 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. boosted its holdings in Novartis by 1.6% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 45,425 shares of the company’s stock valued at $3,814,000 after purchasing an additional 716 shares during the last quarter. Institutional investors own 10.82% of the company’s stock.

In related news, major shareholder Institutes For Biomed Novartis purchased 766,666 shares of Novartis stock in a transaction dated Monday, April 23rd. The shares were acquired at an average cost of $15.00 per share, with a total value of $11,499,990.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.01% of the stock is currently owned by insiders.

Several research firms have weighed in on NVS. JPMorgan Chase reiterated a “neutral” rating on shares of Novartis in a report on Thursday, January 18th. Deutsche Bank reiterated a “neutral” rating on shares of Novartis in a report on Tuesday, April 10th. Finally, ValuEngine lowered shares of Novartis from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. Five research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $89.81.

Novartis opened at $77.60 on Thursday, MarketBeat reports. The company has a market capitalization of $181.53 billion, a PE ratio of 16.13, a P/E/G ratio of 1.76 and a beta of 0.76. Novartis has a 1 year low of $77.85 and a 1 year high of $78.03. The company has a current ratio of 1.17, a quick ratio of 0.91 and a debt-to-equity ratio of 0.33.

Novartis (NYSE:NVS) last released its quarterly earnings results on Thursday, April 19th. The company reported $1.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.03. The business had revenue of $12.69 billion for the quarter, compared to the consensus estimate of $12.45 billion. Novartis had a net margin of 16.04% and a return on equity of 16.23%. The business’s revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.13 EPS. research analysts forecast that Novartis will post 5.28 EPS for the current year.

About Novartis

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.